BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants t ...

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the ...

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize t ...

SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on develop ...

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares ("Shares") of its common stock or, in lieu of Shares, pre-funded warrants (the "Pre-Funded Warrants") to purchase Shares (the "Offering"). s ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP of Commercial Rachael Nokes - CFO Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Naz Rahman - Maxim Group Douglas Tsao - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the scPharmaceuticals First Quarter 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of in ...

BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. Business Update • For the first quarter ended March 31, 2024, scPharmaceuticals reports: • Net FUROSCIX revenue of ...

scPharmaceuticals Inc (NASDAQ:SCPH) Q4 2023 Results Conference Call March 13, 2024 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer John Mohr - Senior Vice President of Clinical Development & Medical Affairs Conference Call Participants Rosa Chen - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H. C. Wainwright Chase Knickerbocker - Craig-Hallum Naz Rahman - Maxi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Washington, D.C. 20549 Commission File Number 001-38293 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...